Autoantibodies against IL-17A, IL-17F and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I

  1. Lookup NU author(s)
  2. Professor Andrew Cant
  3. Dr Mario Abinun
  4. Dr Desa Lilic
Author(s)Puel A, Natividad A, Chrabieh M, Döffinger R, Barcenas-Morales G, Picard C, Ouachée-Chardin M, Toulon A, Bustamante J, Al-Muhsen S, Arkwright PD, Costigan C, McConnell V, Cant AJ, Abinun M, Polak M, Bougnères PF, Kumararatne D, Blanche S, Fischer AM, Bodemer C, Abel L, Lilic D, Casanova JL
Publication type Article
JournalJournal of Experimental Medicine
Year2010
Volume207
Issue2
Pages291-297
ISSN (print)0022-1007
ISSN (electronic)1540-9538
Full text is available for this publication:
Most patients with autoimmune polyendocrine syndrome type I (APS-I) display chronic mucocutaneous candidiasis (CMC). We hypothesized that this CMC might result from autoimmunity to interleukin (IL)-17 cytokines. We found high titers of autoantibodies (auto-Abs) against IL-17A, IL-17F, and/or IL-22 in the sera of all 33 patients tested, as detected by multiplex particle-based flow cytometry. The auto-Abs against IL-17A, IL-17F, and IL-22 were specific in the five patients tested, as shown by Western blotting. The auto-Abs against IL-17A were neutralizing in the only patient tested, as shown by bioassays of IL-17A activity. None of the 37 healthy controls and none of the 103 patients with other autoimmune disorders tested had such auto-Abs. None of the patients with APS-I had auto-Abs against cytokines previously shown to cause other well-defined clinical syndromes in other patients (IL-6, interferon [IFN]-, or granulocyte/macrophage colony-stimulating factor) or against other cytokines (IL-1β, IL-10, IL-12, IL-18, IL-21, IL-23, IL-26, IFN-β, tumor necrosis factor [], or transforming growth factor β). These findings suggest that auto-Abs against IL-17A, IL-17F, and IL-22 may cause CMC in patients with APS-I.
PublisherRockefeller University Press
URLhttp://dx.doi.org/10.1084/jem.20091983
DOI10.1084/jem.20091983
NotesD. Lilic and J.-L. Casanova have shared senior authorship of this article. See also Editorial from this journal issue: Maxmen, A. Antibodies attack IL-17. Journal of Experimental Medicine 2010, 207(2): 264-265.
Actions    Link to this publication
Share